Chronic Myeloid Leukemia Coverage from Every Angle
Advertisement
Advertisement

Recent News

Novel Strategy to Inhibit Imatinib Resistance With Indirubin
Tyrosine Kinase Inhibitor Discontinuation in CML: Real-World Experience
Role of CCN3 Hypermethylation in CML
Update on Issues in Treating and Monitoring Patients With CML
Sensitivity of Molecular Monitoring in TKI Stopping Trials in CML
Rare Case of Unilateral CML Retinopathy Reported
Monitoring First-Line Treatment of Nilotinib in CML
HOPA 2019: Considering Comorbidities When Selecting a Second-Generation TKI in CML
Medication Adherence and Cost for Patients With CML
Identifying Imatinib-Resistant Mutations in Patients With CML
Psychological Experience of Living With CML: From the Patient Perspective
Imatinib’s Potential Long-Term Effects on Pregnancy and Implantation
Study Finds Novel Compound Reduces Survival of Imatinib-Resistant CML Cells
Translational CML Study of Nilotinib Versus Imatinib: Focus on Adipocyte Toxicity
Does Imatinib Affect Bone Marrow Morphology in Chronic Myeloid Leukemia?
Achievement of Treatment-Free Remission in CML Influenced by Transcript Variant
MD Anderson–Led Research Initiative Seeks New Agents for CML and Other Leukemias
Novel Genetic Biomarker for Predicting Response to Imatinib Therapy for CML
Feasibility of Stopping Lifelong Tyrosine Kinase Inhibitor Therapy in CML
Interim TIGER Trial Results With Nilotinib Plus Interferon in CML
Controlling Graft-vs-Host Disease in Older Patients After Stem Cell Transplantation
Use of Risk Stratification Scores in Elderly Patients With CML
First-Line Nilotinib Treatment In Newly Diagnosed CML
TKI Resistance and Compound BCR-ABL1 Kinase Domain Mutations in Leukemia
Novel Therapeutic Strategy May Improve Treatment Efficacy Against Leukemia
ASH 2018: 5-Year Analysis of Imatinib vs. Dasatinib in Newly Diagnosed Chronic Phase CML
ASH 2018: Making the Decision to Switch to Dasatinib From Imatinib in CML
ASH 2018: Intermittent TKI Therapy in Elderly Patients With CML
ASH 2018: Might Asciminib Become a New Treatment Option in CML?
ASH 2018: Is Generic Imatinib as Effective as Its Brand Counterpart in Chronic Phase CML?
ASH 2018: Cardiovascular Events Associated With Ponatinib Treatment of CML
Rare Case of CML After Transplantation in Patient With Multiple Myeloma


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.